Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer

Molecular Therapy

Volumn 22, Issue 4, 2014, Pages 828-841

  Camorani, Simona ^a,b   Esposito, Carla L ^a   Rienzo, Anna ^a   Catuogno, Silvia ^a   Iaboni, Margherita ^b   Condorelli, Gerolama ^a,b   De Franciscis, Vittorio ^a   Cerchia, Laura ^a  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GINT4 T APTAMER; IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG; APTAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIMERIZATION; DOWN REGULATION; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG SCREENING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIMARY CELL CULTURE; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; TRANSACTIVATION; ANTAGONISTS AND INHIBITORS; CELL MOTION; GENETICS; GLIOMA; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TUMOR CELL LINE;

APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GLIOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SIGNAL TRANSDUCTION;

EID: 84897573237     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.300     Document Type: Article

References (50)

1. Fredriksson, L, Li, H and Eriksson, U (2004). The PDGF family: Four gene products form five dimeric isoforms. Cytokine Growth Factor Rev 15: 197-204
2. Ostman, A (2004). PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15: 275-286
3. Yarden, Y, Escobedo, JA, Kuang, WJ, Yang-Feng, TL, Daniel, TO, Tremble, PM et al. (1986). Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature 323: 226-232
4. Matsui, T, Heidaran, M, Miki, T, Popescu, N, La Rochelle, W, Kraus, M et al. (1989). Isolation of a novel receptor cDNA establishes the existence of two PDGF receptor genes. Science 243: 800-804
5. Gilbertson, RJ and Clifford, SC (2003). PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet 35: 197-198
6. Kilic, T, Alberta, JA, Zdunek, PR, Acar, M, Iannarelli, P, O'Reilly, T et al. (2000). Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 60: 5143-5150
7. Shamah, SM, Stiles, CD and Guha, A (1993). Dominant-negative mutants of plateletderived growth factor revert the transformed phenotype of human astrocytoma cells. Mol Cell Biol 13: 7203-7212
8. Cerchia, L and de Franciscis, V (2011). Nucleic acid aptamers against protein kinases. Curr Med Chem 18: 4152-4158
9. Esposito, CL, Passaro, D, Longobardo, I, Condorelli, G, Marotta, P, Affuso, A et al. (2011). A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS ONE 6: E24071
10. Cerchia, L, Esposito, CL, Camorani, S, Rienzo, A, Stasio, L, Insabato, L et al. (2012). Targeting Axl with an high-Affinity inhibitory aptamer. Mol Ther 20: 2291-2303
11. Cerchia, L, Esposito, CL, Jacobs, AH, Tavitian, B and de Franciscis, V (2009). Differential SELEX in human glioma cell lines. PLoS ONE 4: E7971
12. Cerchia, L, Ducongé, F, Pestourie, C, Boulay, J, Aissouni, Y, Gombert, K et al. (2005). Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol 3: E123
13. Mahlknecht, G, Maron, R, Mancini, M, Schechter, B, Sela, M and Yarden, Y (2013). Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc Natl Acad Sci USA 110: 8170-8175
14. Li, N, Nguyen, HH, Byrom, M and Ellington, AD (2011). Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS ONE 6: E20299
15. Keefe, AD, Pai, S and Ellington, A (2010). Aptamers as therapeutics. Nat Rev Drug Discov 9: 537-550
16. Esposito, CL, Catuogno, S, de Franciscis, V and Cerchia, L (2011). New insight into clinical development of nucleic acid aptamers. Discov Med 11: 487-496
17. Ye, M, Hu, J, Peng, M, Liu, J, Liu, J, Liu, H et al. (2012). Generating Aptamers by Cell-SELEX for Applications in Molecular Medicine. Int J Mol Sci 13: 3341-3353
18. Cerchia, L and de Franciscis, V (2010). Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol 28: 517-525
19. Burnett, JC and Rossi, JJ (2012). RNA-based therapeutics: Current progress and future prospects. Chem Biol 19: 60-71
20. Thiel, KW and Giangrande, PH (2010). Intracellular delivery of RNA-based therapeutics using aptamers. Ther Deliv 1: 849-861
21. Dagher, R, Cohen, M, Williams, G, Rothmann, M, Gobburu, J, Robbie, G et al. (2002). Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8: 3034-3038
22. Roberts, WG, Whalen, PM, Soderstrom, E, Moraski, G, Lyssikatos, JP, Wang, HF et al. (2005). Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res 65: 957-966
23. Dancey, JE and Chen, HX (2006). Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 5: 649-659
24. Andrae, J, Gallini, R and Betsholtz, C (2008). Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22: 1276-1312
25. Shen, J, Vil, MD, Prewett, M, Damoci, C, Zhang, H, Li, H et al. (2009). Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. Neoplasia 11: 594-604
26. Sano, H, Ueda, Y, Takakura, N, Takemura, G, Doi, T, Kataoka, H et al. (2002). Blockade of platelet-derived growth factor receptor-beta pathway induces apoptosis of vascular endothelial cells and disrupts glomerular capillary formation in neonatal mice. Am J Pathol 161: 135-143
27. Song, S, Ewald, AJ, Stallcup, W, Werb, Z and Bergers, G (2005). PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7: 870-879
28. Green, LS, Jellinek, D, Jenison, R, Ostman, A, Heldin, CH and Janjic, N (1996). Inhibitory DNA ligands to platelet-derived growth factor B-chain. Biochemistry 35: 14413-14424
29. Abouantoun, TJ and MacDonald, TJ (2009). Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor. Mol Cancer Ther 8: 1137-1147
30. Conti, L, Pollard, SM, Gorba, T, Reitano, E, Toselli, M, Biella, G et al. (2005). Nicheindependent symmetrical self-renewal of a mammalian tissue stem cell. PLoS Biol 3: E283
31. Das, A, Banik, NL and Ray, SK (2009). Molecular mechanisms of the combination of retinoid and interferon-gamma for inducing differentiation and increasing apoptosis in human glioblastoma T98G and U87MG cells. Neurochem Res 34: 87-101
32. Saito, Y, Haendeler, J, Hojo, Y, Yamamoto, K and Berk, BC (2001). Receptor heterodimerization: Essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol Cell Biol 21: 6387-6394
33. Carrasco-García, E, Saceda, M, Grasso, S, Rocamora-Reverte, L, Conde, M, Gómez-Martínez, A et al. (2011). Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. Exp Cell Res 317: 1476-1489
34. Ranza, E, Mazzini, G, Facoetti, A and Nano, R (2010). In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation. J Neurooncol 96: 349-357
35. Sheng, Z, Li, L, Zhu, LJ, Smith, TW, Demers, A, Ross, AH et al. (2010). A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nat Med 16: 671-677
36. Ostermann, S, Csajka, C, Buclin, T, Leyvraz, S, Lejeune, F, Decosterd, LA et al. (2004). Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10: 3728-3736
37. Woo, M, Hakem, R, Soengas, MS, Duncan, GS, Shahinian, A, Kägi, D et al. (1998). Essential contribution of caspase 3/CPP32 to apoptosis and its associated nuclear changes. Genes Dev 12: 806-819
38. Kim, Y, Kim, E, Wu, Q, Guryanova, O, Hitomi, M, Lathia, JD et al. (2012). Plateletderived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Dev 26: 1247-1262
39. Dong, Y, Han, Q, Zou, Y, Deng, Z, Lu, X, Wang, X et al. (2012). Long-Term exposure to imatinib reduced cancer stem cell ability through induction of cell differentiation via activation of MAPK signaling in glioblastoma cells. Mol Cell Biochem 370: 89-102
40. Hermanson, M, Funa, K, Hartman, M, Claesson-Welsh, L, Heldin, CH, Westermark, B et al. (1992). Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52: 3213-3219
41. Stommel, JM, Kimmelman, AC, Ying, H, Nabioullin, R, Ponugoti, AH, Wiedemeyer, R et al. (2007). Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318: 287-290
42. Velpula, KK, Dasari, VR, Asuthkar, S, Gorantla, B and Tsung, AJ (2012). EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells. Transl Oncol 5: 379-392
43. Yu, D, Wang, D, Zhu, FG, Bhagat, L, Dai, M, Kandimalla, ER et al. (2009). Modifications incorporated in CpG motifs of oligodeoxynucleotides lead to antagonist activity of toll-like receptors 7 and 9. J Med Chem 52: 5108-5114
44. Zhou, J, Neff, CP, Swiderski, P, Li, H, Smith, DD, Aboellail, T et al. (2013). Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther 21: 192-200
45. Cheng, C, Chen, YH, Lennox, KA, Behlke, MA and Davidson, BL (2013). In vivo SELEX for Identification of Brain-penetrating Aptamers. Mol Ther Nucleic Acids 2: E67
46. Dilnawaz, F, Singh, A, Mewar, S, Sharma, U, Jagannathan, NR and Sahoo, SK (2012). The transport of non-surfactant based paclitaxel loaded magnetic nanoparticles across the blood brain barrier in a rat model. Biomaterials 33: 2936-2951
47. Kim, Y, Wu, Q, Hamerlik, P, Hitomi, M, Sloan, AE, Barnett, GH et al. (2013). Aptamer identification of brain tumor-initiating cells. Cancer Res 73: 4923-4936
48. Gao, H, Qian, J, Cao, S, Yang, Z, Pang, Z, Pan, S et al. (2012). Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials 33: 5115-5123
49. Esposito, CL, D'Alessio, A, de Franciscis, V and Cerchia, L (2008). A cross-Talk between TrkB and Ret tyrosine kinases receptors mediates neuroblastoma cells differentiation. PLoS ONE 3: E1643
50. Costes, SV, Daelemans, D, Cho, EH, Dobbin, Z, Pavlakis, G and Lockett, S (2004). Automatic and quantitative measurement of protein-protein colocalization in live cells. Biophys J 86: 3993-4003.